Sanofi responds to patent spat with Amgen as Supreme Court arguments set for March
The newest step in the saga between Amgen and Sanofi’s patent tug-of-war is in Sanofi’s court, just a matter of weeks before oral arguments.
Just over a month after Amgen filed a response to the Supreme Court against Sanofi, the French pharma is countering Amgen’s claims that the Federal Circuit’s previous standard harms innovation.
Sanofi said in its filing Friday that Amgen obtained additional patents to try and broadly claim the entire genus of PCSK9-blocking antibodies after Sanofi and Regeneron had already developed Praluent. On top of that, Sanofi claims that Amgen’s rationale that a Federal Circuit standard harms innovation is not entirely true.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.